by admin | 7 June 2019 | News
New York/London, 7 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 5 June 2019, Panetta Partners... by admin | 3 June 2019 | News
New York/London, 3 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 31 May 2019, Panetta Partners... by admin | 31 May 2019 | News
Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology and immunology, today announces that at the Annual General Meeting of the... by admin | 28 May 2019 | News
New York / London May 28, 2018 Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced that it will be presenting at... by admin | 7 May 2019 | News
Tiziana Life Sciences plc (the “Company”) Notice of Annual General Meeting Tiziana Life Sciences plc announces that its Annual General Meeting will be held at 10:00 a.m. on Friday 31 May 2019 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad... by admin | 2 May 2019 | News
Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) PDMR dealings New York/London, 1 May 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative... by admin | 1 May 2019 | News
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS... by admin | 25 April 2019 | News
Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) New York/London, 25 April 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative... by admin | 24 April 2019 | News
Tiziana Reports encouraging interim clinical data from an ongoing Phase 2a Clinical Trial with Milciclib in Patients with advanced liver cancer 80% of patients who completed treatment within the trial’s timeframe requested to continue treatment on compassionate use... by admin | 16 April 2019 | News
TR-1 – Notification of Major Holdings New York/London, 15 April 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today... by admin | 4 April 2019 | News
Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Financial Results for the Year Ended 31 December 2018 London, 4 April 2019 – Tiziana Life Sciences plc (AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to... by admin | 20 March 2019 | News
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS... by admin | 7 February 2019 | News
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Directorate Change New York/London, 7 February 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM:... by admin | 11 December 2018 | News
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Exercise of Warrants & Issue of Equity New York/London, 11 December 2018... by admin | 3 December 2018 | News
New York/London, 3 December 2018 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the... by admin | 28 November 2018 | News
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc(“Tiziana” or the “Company”) Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human... by admin | 26 November 2018 | News
London, 26 November 2018 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company”), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that in... by admin | 23 November 2018 | News
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT... by admin | 20 November 2018 | News
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT... by admin | 20 November 2018 | News
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT... by admin | 26 October 2018 | News
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc (“Tiziana” or the “Company”) London, October 26, 2018 – Tiziana Life Sciences plc (AIM: TILS), a UK... by admin | 18 October 2018 | News
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT... by admin | 28 April 2017 | News
Dr. Kunwar Shailubhai talks to Tip TV about Tiziana receiving approval to start Phase IIa trials to test its leading compound milciclib, a CDK inhibitor as a treatment for hepatocellular carcinoma (HCC).